Astellas Pharma v. Eurofarma: Appeal Dismissed Over Modified Release Pharma Patent
Astellas Pharma, Inc. brought an appeal before the Court of Justice of São Paulo against Eurofarma Laboratorios SA concerning Brazilian patent BRPI0919466B1, which covers modified release oral pharmaceutical compositions and their manufacturing process. The Court of Justice dismissed the appeal on 14 May 2025, leaving the lower-court outcome intact without a merits ruling at the appellate level.
Brazilian pharma patent appeal ends without merits adjudication
Astellas Pharma, Inc., the Japanese originator pharmaceutical company, filed an appeal before the Court of Justice of São Paulo (Case No. 2035879-63.2025.8.26.0000) against Brazilian generic manufacturer Eurofarma Laboratorios SA. The dispute centres on patent BRPI0919466B1, which protects a modified release oral pharmaceutical composition and the process for making it — a formulation technology with broad relevance to sustained-release drug delivery products.
The Court of Justice of São Paulo dismissed the appeal on 14 May 2025. A dismissal at appellate level without a merits determination means the appellate court declined to review the substance of Astellas’s arguments, allowing the lower-court position to stand. The Basis of Termination recorded is ‘Appeal Dismissed’, consistent with a procedural rather than substantive resolution. No settlement terms or damages figures are disclosed in the public record.
Because the filing date is absent from the available case data, the total duration of proceedings cannot be calculated. The dismissal of an appeal on non-merits grounds typically suggests procedural deficiencies — such as standing, timeliness, or formal requirements — rather than a finding on patent validity or infringement. What drove the specific procedural outcome and whether Astellas retains further recourse in Brazilian courts remains unclear from the public record alone.
Filing to Appeal Dismissed in 0 days
Case closed 14 May 2025; filing date not on public record
Appeal dismissed: what the ruling means for both parties
Procedural dismissal — no merits ruling on the patent
When an appellate court dismisses an appeal without reaching the merits, it means the court found a procedural barrier — such as lack of standing, failure to meet filing requirements, or jurisdictional defects — that prevented substantive review. The underlying lower-court decision is left intact, but the appellate court has made no finding on patent validity or infringement under BRPI0919466B1.
No merits determinationAstellas loses appellate review without a ruling on validity
For Astellas Pharma as appellant, dismissal without merits adjudication means the appeal avenue is closed at this level without any vindication of its patent position. The company may need to assess whether alternative procedural routes — such as a further appeal to a higher Brazilian court — are available and viable, depending on the grounds for dismissal.
Appellant route closed at this levelEurofarma retains lower-court position by default
Eurofarma Laboratorios SA, as appellee, benefits from the appeal’s dismissal: the lower-court outcome stands without being disturbed by appellate review. However, because the dismissal is procedural rather than substantive, this outcome does not constitute a definitive ruling that Eurofarma’s product or conduct is non-infringing or that the patent is invalid.
Lower-court outcome preservedPatent position on modified release formulations remains unresolved
A procedural dismissal without merits review leaves the enforceability of BRPI0919466B1 commercially uncertain. Other generic manufacturers active in the Brazilian modified release oral pharmaceutical market should monitor whether Astellas pursues further proceedings, as a future merits ruling — in either direction — could materially affect freedom to operate in this formulation space.
Enforceability remains uncertainFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Astellas Pharma, Inc. | Company | Originator pharmaceutical company — holder of BRPI0919466B1Search in Eureka ↗ |
| Defendant | EUROFARMA LABORATORIOS SA | Company | Brazilian generic pharmaceutical manufacturer Eurofarma Laboratorios SASearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Justice of Sao PauloSearch in Eureka ↗ |
Official order — verbatim text
The verdict states: ‘the appeal is dismissed.’ This phrasing confirms a procedural termination at the appellate level of the Court of Justice of São Paulo — the court did not engage with the substantive arguments on patent BRPI0919466B1. No finding was made on validity, infringement, or the merits of either party’s position. The dismissal leaves the lower-court outcome undisturbed but should not be read as a judicial endorsement of that outcome. Both parties’ underlying legal positions on the patent remain formally unadjudicated at this court level.
BRPI0919466B1 — modified release oral pharmaceutical composition
BRPI0919466B1 is a Brazilian granted patent (B1 status indicating granted with examination) protecting a modified release oral pharmaceutical composition and the process for its manufacture. Modified release formulations — encompassing sustained, extended, and controlled release technologies — are a high-value category in pharmaceutical development, enabling once-daily dosing, improved patient compliance, and differentiated product life-cycle management. The patent’s scope over both the composition and the manufacturing process suggests broad coverage that could potentially capture a range of generic equivalents.
In the Brazilian pharmaceutical market, formulation patents such as BRPI0919466B1 are frequently the front line of originator defence against generic entry after primary compound patents expire. Eurofarma, as one of Brazil’s largest domestic generic manufacturers, is a natural litigation counterparty for originator companies seeking to protect formulation IP. The unresolved appellate posture of this case means competitors and in-licensing parties should treat the patent’s enforceability status as live and subject to change.
Should you run an FTO against BRPI0919466B1?
Any pharmaceutical manufacturer, contract development and manufacturing organisation (CDMO), or generic company developing or commercialising modified release oral dosage forms for the Brazilian market should treat BRPI0919466B1 as an active FTO priority. The patent covers both the composition and the manufacturing process, meaning FTO exposure could arise at the formulation design stage or at manufacturing. The unresolved litigation status — procedural dismissal, no merits ruling — adds urgency: enforcement risk has not been extinguished.
PatSnap Eureka’s FTO Search Agent allows R&D and IP teams to map claim scope against proposed formulation designs, identify prior art that may affect claim interpretation, and monitor prosecution and litigation history for BRPI0919466B1 and related Astellas patents in Brazil. Setting up a patent monitoring alert ensures your team receives immediate notification if new proceedings are filed or if the patent’s legal status changes.
Run a freedom-to-operate analysis on BRPI0919466B1 to assess your product’s exposure
Run FTO in Eureka →Similar modified release pharmaceutical patent cases in Brazilian courts
Related litigation involving modified release oral pharmaceutical formulation patents before Brazilian state and federal courts, including São Paulo Court of Justice proceedings.
What this case signals for the Brazilian pharma patent IP landscape
Procedural dismissals in Brazilian appellate courts can leave patent enforceability unresolved — a material risk for both originators and generics in the modified release drug delivery sector.
Procedural dismissals do not resolve infringement or validity
This case closed without any appellate court finding on whether BRPI0919466B1 is valid or infringed. Companies relying on a dismissal as a clearance signal for modified release formulations should exercise caution — the patent remains in force and its enforceability has not been tested on the merits at appellate level.
Brazilian appellate procedure can bar substantive review
The Court of Justice of São Paulo’s dismissal suggests Astellas’s appeal may have failed to satisfy procedural requirements under Brazilian civil procedure. IP teams operating in Brazil should ensure appeals are filed with rigorous attention to standing, form, and timeliness to preserve access to merits-level review.
Astellas v EUROFARMA — key questions answered
The Court of Justice of São Paulo dismissed Astellas Pharma’s appeal on 14 May 2025. The dismissal is procedural — no merits ruling was issued on patent BRPI0919466B1’s validity or Eurofarma’s alleged infringement. The lower-court outcome was left intact by default.
BRPI0919466B1 is a Brazilian granted patent protecting a modified release oral pharmaceutical composition and the process for manufacturing it. Modified release formulations control the rate or timing of drug release, offering clinical and commercial advantages. The patent’s dual coverage of composition and process broadens its potential enforcement reach against generic manufacturers.
An appeal dismissal on procedural grounds does not constitute a finding that the patent is valid, invalid, infringed, or not infringed. The lower-court position stands, but the patent’s enforceability has not been affirmatively confirmed or denied at appellate level. The patent owner may retain options to pursue further proceedings depending on the grounds for dismissal.
Not definitively. A procedural appeal dismissal does not constitute a finding of non-infringement or patent invalidity. Eurofarma benefits from the lower-court outcome standing, but BRPI0919466B1 remains a granted patent in Brazil. Any manufacturer should obtain qualified Brazilian IP legal advice before treating this outcome as a freedom-to-operate clearance.
Under Brazilian civil procedure, appeals can be dismissed for reasons including failure to meet filing deadlines, lack of standing, non-payment of court fees, formal deficiencies in the appeal brief, or lack of jurisdiction. A procedural dismissal means the appellate court identified one of these barriers before reaching the substance of the patent arguments. The specific ground for dismissal in this case is not disclosed in the available public record.
PatSnap Eureka searches patents and litigation data to answer instantly.